Delphinol® is a patented, standardized Maqui Berry (Aristotelia chilensis) extract developed by MNL Group, standardized to a minimum of 35% total anthocyanins and 25% delphinidins — the highest natural concentration of these compounds found in any known fruit. Delphinol® has been evaluated in multiple human clinical trials across metabolic regulation, skin vitality, and oxidative stress reduction, with results published in peer-reviewed journals. Laboratory analysis confirmed full-spectrum antioxidant activity against all five major reactive oxygen species, with an ORAC 5.0 value of 30,852 µmol Trolox equivalents per gram, distinguishing it from single-pathway antioxidant ingredients.

Delphinol® lowered glycosylated hemoglobin (HbA1c) from 5.65% to 5.35% over 90 days in a three-month clinical trial with 31 prediabetic individuals at the Pontificia Universidad Católica de Chile (Panminerva Medica, 2016), at a dose of 180 mg per day. The reduction was statistically significant (p = 0.003) and moved participants from a range associated with elevated metabolic risk toward normal values. The same trial showed LDL cholesterol decreased by approximately 14% (p < 0.001), HDL cholesterol increased significantly from the second month onward (p < 0.001), and total cholesterol declined over the three-month period. A separate dose-finding study showed that Delphinol® reduced postprandial glucose peaks within 60 minutes of ingestion at doses of 60 mg and above. Supplementation was well tolerated, with no adverse effects and no significant changes in liver enzyme values.

Delphinol® increased skin elasticity by 39% and dermal thickness by 22% over 90 days in a clinical study where it was combined with collagen, hibiscus, and vitamin C, with more than 90% of participants reporting visible improvement in skin firmness after 12 weeks (Clinical, Cosmetic and Investigational Dermatology, 2018). A separate randomized, double-blind, placebo-controlled pilot study conducted in Japan, using 60 mg of Delphinol® per day for 8 weeks, found significant improvements in skin brightness, collagen content, and facial skin redness compared to placebo in healthy female subjects aged 27 to 57 (Journal of Cosmetics, Dermatological Sciences and Applications, 2020).

Delphinol® has been clinically studied across three areas: metabolic health (glucose metabolism and lipid profile, including a three-month trial in prediabetic individuals), skin vitality and healthy aging (elasticity, dermal thickness, collagen content, and skin tone), and oxidative stress reduction (including reduced oxidized LDL and F2-isoprostanes in a trial involving smokers). Across these applications, Delphinol® is supported by more than 15 years of clinical and pre-clinical research. All published studies are available at mnl-group.com/en/clinical-studies.

Delphinol® works through several complementary mechanisms driven by its delphinidin glycosides. Laboratory studies have shown that delphinidins neutralize all five major reactive oxygen species — peroxyl radicals, hydroxyl radicals, peroxynitrite anions, singlet oxygen, and superoxide anion radicals — making Delphinol® a full-spectrum antioxidant. At the cellular level, delphinidins downregulate NF-κB activation, a driver of chronic low-grade inflammation; activate PPARγ receptors involved in glucose metabolism and insulin sensitivity; and inhibit α-glucosidase, an enzyme involved in carbohydrate digestion and postprandial glucose absorption. This multi-pathway profile is consistent with the range of health outcomes observed across Delphinol®'s clinical studies.

The clinically studied dose of Delphinol® ranges from 60 mg to 180 mg per day depending on the health application. Skin-related studies used 60 mg per day, while metabolic outcomes (HbA1c and lipid profile) were achieved at 180 mg per day. The acute dose-finding study for postprandial glucose found measurable, dose-dependent effects at 60 mg and above. As Delphinol® is a B2B ingredient, final product dosage recommendations are determined by the formulating brand in accordance with applicable regulations in their market.

Delphinol® is used by nutraceutical and supplement brands across North America, Europe, and Asia. If you are a consumer looking for products formulated with Delphinol® for metabolic health, skin vitality, or antioxidant support, you can find an updated list of available brands and products at mnl-group.com/en/find-products.

Delphinol® is available as a B2B ingredient in powder form, suitable for capsules, tablets, sachets, and functional beverages. To request technical documentation, samples, or commercial information, contact our team at mnl-group.com/contact.